08/11/2016
Common side effects of anti-cancer therapies
Disclosure • Honoraria: Speaker and Advisory Board: Roche, Pfizer, Novartis, Celgene, Apotex Astellas
Incorporated,
Kian Khodadad, MD Assistant Professor in Medicine Dalhousie University Cape Breton Cancer Centre Sydney November 9, 2016
Learning Objective • To review potential side effects of systemic anti-cancer therapies, particularly immunotherapies • To review common systemic therapies for common solid tumors • To review the management of adverse reactions to systemic anticancer therapies particularly irARs
Proportion of deaths due to cancer and other causes, Canada, 2012
Audience • Family Doctors and ER physicians • Nursing staff • Pharmacists
Lifetime probability of dying from cancer, Canada 2010
Canadian Cancer Statistics 2016 Canadian Cancer Statistics 2016
1
08/11/2016
Percent distribution of estimated cancer deaths, by sex, Canada 2016
Geographic distribution of estimated cancer deaths and age-standard mortality rates by province and territory, both sexes, Canada 2016
Canadian Cancer Statistics 2016 Canadian Cancer Statistics 2016
Goal of cancer treatment
Categories of systemic therapies
- Curative: eradicate cancer cells, prevention of disease recurrence *Adjuvant: post local therapy ( surgery, radiation) *Neo-adjuvant: prior to local therapy *Concurrent chemoRT - Palliative: provide comfort, improve/prolong QoL
• Cytotoxic agents (chemotherapy): alkylating, anthracyclines, platinum • Hormonal therapy: Tamoxifen, aromatase inhibitors (letrozole, anastrozole, exemestane), biclatumide, enzalutamide, abiraterone • Antibodies: EGFRI (cetuximab, panitumumab, trastuzumab, pertuzumab), VEGFI (bevacizumab)
Categories of systemic therapies • Immunotherapies: immune checkpoint inhibitor (nivolumab, pemprolizumab, ipilimumab) • Targeted therapies (TKI): BRAF (vemurafenib), MEK (trametinib), VEGFR (pazopanib, axitinib, sunitinib, sorafenib), EGFR (Erlotinib, afatenib), ALK (crizotinib, alectinib) • Tumour vaccine: sipuleucel-T
Cytotoxic Agents (chemotherapy)
2
08/11/2016
Mechanisms of action of cytotoxic agents (cell cycle dependent or independent)
Cytotoxic Agents cathegories • Alkylating agents (e.g. cyclophosphamide) • Antimetabolites (e.g. MTX, 5FU) • Vinca alkaloids (e.g. Vinblastin, vinorelbine) • Antimitotic antibiotic (e.g. Doxorubicin, bleomycin) • Taxanes (docetaxel, paclitaxel) • Miscellaneous compounds: e.g. Platinum, nitrosurea
https://www.mycancergenome.org/content/molecular-medicine/pathways/cytotoxic-chemotherapy-mechanisms-of-action
Cytotoxic agents - common chemo protocols -
Cytotoxic agents - common chemo protocols -
• Breast cancer: AC(doxorubicin/cyclophosphamide),
• Prostate cancer: Docetaxel, cabazitaxel, mitoxantrone
TC(docetaxel/cyclophosphamide), FEC-D (5FU/epirubicin/cyclophosphamide-docetaxel), dose-dense AC/T • Colon cancer: oral capecitabine, 5FU, XELOX (cap/oxaliplatin), FOLFOX (5FU/FA/oxaliplatin), FOLFIRI (5FU/FA/irinotecan) • Lung cancer: paclitaxel/carboplatin, etoposide/platin, vinorelbine/cisplatin, gemcitabine/carboplatin, pemetrexed/platinum
Cytotoxic agents - Side Effects • Nausea/Vomiting • Constipation/Diarrhea • Mucositis • Thrombocytopenia (pemetrexed, gemcitabine, carboplatin) • Capillary leak syndrome (gemcitabine, docetaxel) • Cardiotoxicity anthracyclines: type I cardiotoxicity: dose related, underlying comorbidities (HTN, CAD, HLP), age, causing CHF, irreversible, prophylactic beta blockers/ACE inhibitors? 5FU/cape.: MI • Afebrile/Febrile neutropenia
Cytotoxic agents - Side Effects • Carcinogenic: AML (e.g. anthracyclins) • Teratogenic • Reproductive toxicity: infertility and early ovarian failure • Local thrombophelebitis/extravasation: hydrocortisone, analgesics, care of ulcer when develops • Hyperglycemia: corticosteroids • Hypersensitivity/anaphylactic reactions
3
08/11/2016
Cytotoxic agents Side Effects • Tumor lysis syndrome • Electrolyte imbalances: Hypocalcemia,
hypokalemia, hypomagnesemia (cetuximab, cisplatin) • Pulmonary toxicity: pulmonary fibrosis • Nephrotoxicity: cisplatin • Neurotoxicty: taxanes (paclitaxel, docetaxel), vinca alkaloids (vincristine, vinorelbine), cisplatin, oxaliplatin (early- and late-onset)
5 Fluorouracil/capecitabine • Cardiovascular: angina pectoris, cardiac arrhythmia, cardiac failure, ischemic heart disease, MI • Dermatologic: palmar-plantar erythrodysesthesia, skin fissures • Ophthalmic: lacrimal stenosis, lacrimation, photophobia • Dihydropyrimidine dehydrogenase (DPD) deficiency: diarrhea, neutropenia, neurotoxicity Warfarin interaction
Hormonal Therapies
Hormonal Therapies
Tamoxifen - side effects • Thromboembolic events 2-5% • vasomotor symptoms: hot flashes, sweating 5-20% • vaginal bleeding 2-23% (regular gyne exam) • endometrial cancer 1% • altered lipid profile with decreased total/LDL/HDL cholesterol • depression 5-10% • cataracts 65 years) • venous thromboembolism 5-20% • wound healing complications 5-20% (bevacizumab should be held for at least 28 days prior to elective surgery, and should not be initiated for at least 28 days following major surgery and until surgical wound is fully healed to prevent complications)
• GI fistula/perforation 3% • epistaxis 20-25% • mucocutaneous hemorrhage 20-40%, • reversible posterior leukoencephalopathy syndrome (RLPS) 1% (seizures, headache, altered mental status, visual disturbance, or cortical blindness, with or without associated hypertension, brain imaging confirms the diagnosis) • proteinuria 65 years)
Novel Immunotherapies
prior or concurrent use of antihypertensive medications higher cumulative dose of anthracycline prior to trastuzumab a lower left ventricular ejection fraction (LVEF) at baseline a declining LVEF (25) at screening
7
08/11/2016
CTLA-4 and PD-1/L1 Checkpoint Blockade for Cancer Treatment Priming phase (lymph node)
- immune checkpoint inhibitors: CTLA4 antibody: Ipilimumab PD-1 blockers: Nivolumab, Pembrolizumab PD-L1 blocker: Atezolizumab - IL-2, IFN, BCG
Effector phase (peripheral tissue) T-cell migration
Dendritic cell
MHC
TCR
TCR
CD28
Dendritic cell
T cell B7
Cancer cell
T cell
T cell
T cell
Immunotherapeutic agents
MHC
PD-1 PD-L1
Cancer cell
CTLA-4
Ribas A. N Engl J Med. 2012;366:2517-2519.
Tumors Shown to Respond to Anti-PD1 or Anti-PD-L1 Therapy
Spectrum of toxicity of immune checkpoint blockade agents
• Melanoma • Pembrolizumab, nivolumab, ipilimumab, RAF/MEK inhibitors
• RCC • NSCLC • Bladder • Head and Neck cancer • Lymphomas • ???
Champiat S et al. Ann Oncol (2016) 27 (4): 559-574
The five pillars of immunotherapy toxicity management
Immune checkpoint blockade toxicities Frequent (>10%) ICB toxicities • Ipilimumab (anti-CTLA4): diarrhea, rash, pruritus, fatigue, nausea, vomiting, decreased appetite and abdominal pain • Nivolumab (anti-PD1): fatigue, rash, pruritus, diarrhea and nausea • Pembrolizumab (anti-PD1): diarrhea, nausea, pruritus, rash, arthralgia and fatigue
Rare ( 20%)
Rare (< 2%)
• Rash, pruritus
• • • •
• Diarrhea/colitis
Occasional (3% to 20%) • Hepatitis/liver enzyme abnormalities • Endocrinopathies: hypophysitis, thyroiditis, adrenal insufficiency
Episcleritis/uveitis Pancreatitis Nephritis Neuropathies, Guillain-Barré, myasthenia gravis • Lymphadenopathy (sarcoid) • Thrombocytopenia • Toxic epidermal necrolysis, StevensJohnson syndrome
Toxicity Grade
• Fevers, chills, lethargy
0
2
4
6
8
10
12
14
Weeks Weber JS, et al. J Clin Oncol. 2012;30:2691-2697. Weber JS, et al. J Clin Oncol. 2015;[Epub ahead of print].
Typical management of irAEs
Weber JS, et al. J Clin Oncol. 2012;30:2691-2697.
Ipilimumab: Managing Immune-Related Adverse Events System GI tract
Management Moderate enterocolitis: hold ipilimumab, administer antidiarrheal. Persistent diarrhea (> 1 wk): systemic corticosteroids. 7+ stools/day: start methylprednisone, permanently discontinue ipilimumab. Consider infliximab for corticosteroid-refractory patients
Skin
Rash (± itching) Blistering/peeling Oral sores
Moderate/nonlocalized rash: hold ipilimumab, start topical or systemic corticosteroids. Severe dermatitis: permanently discontinue ipilimumab, start corticosteroids
Liver
Jaundice Nausea/vomiting
Assess ALT/AST, bilirubin, and thyroid function before each dose and as necessary. Hold ipilimumab if ALT/AST > 2.5 x but ≤ 5 x ULN; permanently discontinue if AST/ALT > 5 x ULN or bilirubin > 3 x ULN. The immunosuppressant mycophenolate can be used for hepatotoxicity in corticosteroid-refractory patients
CNS
Weakness in extremities Numbness/tingling Sensory changes
Moderate neuropathy: hold ipilimumab. New or worsening neuropathy: permanently discontinue ipilimumab. Consider corticosteroids
Headaches Fatigue Behavior/mood changes Menstruation changes Dizziness/light-headedness
Moderate endocrinopathy: hold ipilimumab, start corticosteroids. Endocrine abnormalities can be difficult to detect, due to nonspecific symptoms. Consider having an endocrinologist follow the patient
Vision problems Irritation
Monitor for redness suggesting uveitis, treat with topical steroidal eye drops
Endocrine
Eyes
Champiat S et al. Ann Oncol (2016) 27 (4): 559-574
Symptoms Diarrhea Abdominal pain Dark, bloody stools
Ipilimumab adverse reaction management guide.
9
08/11/2016
Checkpoint Inhibition: Managing Grade 3/4 Treatment-Related AEs Grade 3/4 pneumonitis, nephritis, enterocolitis, hepatitis, or infusionrelated reaction New or worsening neuropathy Any life-threatening or grade 4 AE Any severe or grade 3 recurrent AE Hepatitis associated with AST/ALT > 5 x ULN AST/ALT ≥ 50% ↑ from baseline lasting ≥ 1 wk* Total bilirubin > 3 x ULN
Grade 4 elevation of pancreatic enzymes
Initiate steroid therapy Permanently discontinue PD-1 tx Usually resolves with tx interruption‡
If no improvement in colitis or pneumonitis, infliximab or mycophenolate† If no improvement in hepatitis, consider mycophenolate; infliximab contraindicated
Diarrhea/Colitis
- management • R/O C. diff. and other infectious causes • Stools < 4 × baseline: loperamide, budesonide • Stools ≥ 4 and < 7 × baseline: 1 mg/kg of prednisone • Stools > 7 × baseline or refractory to oral steroids: - Hospitalize for intravenous methylprednisolone (1–2 mg/kg) - Consider colonoscopy and computed tomography scan for further evaluation - Consider infliximab (Remicade 5 mg/kg)
*In pts with liver metastasis who begin treatment with grade 2 elevation of AST/ALT. †Pts receiving ipilimumab may tolerate treatment with PD-1/PD-L1 inhibitor alone. ‡Steroids do not appear to accelerate the rate of improvement.
Pembrolizumab adverse reaction management guide. Nivolumab adverse reaction management guide. Ipilimumab adverse reaction management guide.
Endocrinopaties/Hypophysitis
Pneumonitis
- management -
- management -
• Chemistry panel + TSH (baseline and F/U) • Change may be permanent • Prompt steroids • In case of hypophysitis: levothyroxine, low dose hydrocortisone, medical alert bracelets (adrenal crisis)
Adjunctive Therapies • Bone modifying agents: Bisphosphonate: Zoledronic acid, RANK-L blocker: Denosumab • Filgrastim (G-CSF)
• Cough and dyspnea R/O pulmonary mets, pulmonary disease progression, PE, effusion • Withhold therapy, high dose steroids, O2? • Bronchoscopy
Bone Modifying Agents pamidronic acid
• Indications: cancer-related hypercalcemia, bone metastasis, osteoporosis • Side effects: Bisphosphonates: Bone necrosis (jaw bone necrosis), hypocalcemia 510%, nephrotoxicity 8-18%, myalgia 20%, fever 30-45%, arthralgia, flulike symptoms Denosumab (Prolia, Xgeva): bone necrosis (jaw bone necrosis), hypocalcemia 3-18% • Administer ca/vit D in non-hypercalcemic patients • Hydrate pt prior to treatment • Acetaminophen after administration may reduce the incidence of acute reactions
10
08/11/2016
Osteonecrosis of the jaw (ONJ)
- risk factors • invasive dental procedures (e.g. tooth extraction, dental implants, bony surgery) • cancer diagnosis • concomitant therapy (e.g. chemotherapy, corticosteroids, angiogenesis inhibitors) • poor oral hygiene, ill-fitting dentures, pre-existing dental disease • comorbid disorders (e.g. anemia, infection) • longer duration of bisphosphonate use
Filgrastim (G-CSF)
Filgrastim - indications -
Filgrastim - therapeutic indications -
• Primary prophylaxis:
• Secondary prophylaxis • Therapeutic
• Neutropenia without fever : no established role • Neutropenic fever: controversial; the results of randomized trials have been mixed. Probably in pts with poor clinical outcome: - expected prolonged (>10 day) or profound (65 - pneumonia or other clinically documented infections, sepsis syndrome, invasive fungal infection, prior episode of febrile neutropenia - comorbidities (heart failure, pulmonary embolus, lung, renal, liver, cerebrovascular disease)
Filgrastim
Conclusion
anticipated incidence of neutropenic fever is approximately 20 percent or higher with a given regimen may be appropriate in a number of clinical settings in which the estimated risk of neutropenic fever is between 10 and 20 percent not in a metastatic setting
• Bone pain 5-30%, fever 10-50%, chest pain 5-15%, arthralgia 5-10% • Allergic reactions: usually with the initial exposure 2-10% • Pulmonary toxicity: bleomycin, cyclophosphamide • Capillary leak syndrome 1%: hypotension, hypoalbuminemia, edema, hemoconcentration INF alpha, IL-2, gemcitabine, docetaxel (fluid retention?)
• Treating physician must have a high index of suspicion for potential AE of any anticancer therapy • Communication with other health care workers is very important • Serious adverse events may present initially in a subtle manner • Early treatment makes a difference
11
08/11/2016
Conclusion - Novel Immunotherapies • Routine B/W (endocrine surveillance) is essential • Late SEs may emerge months (or yrs) after exposure to checkpoint inhibitors. • Late SEs may be severe and/or unusual • Patients have to be pressed on AE symptoms, which they will often not volunteer • Family members must be trained to recognize AE • Patients and family members may be educated in the importance of reporting any change from baseline.
Questions?
Other references • UpToDate • BC Cancer Agency Drug Information
Thank You!
12